“…Previously, our research group investigated the mitochondrial targeting of liposomes modified with triphenylphosphonium cationic amphiphiles with different lengths of hydrocarbon tails and at different ratios of amphiphiles/lipids in the case of cancer [ 51 ]. In addition to oncological diseases [ 52 , 53 , 54 ], the mitochondria-targeted drug delivery strategy is gaining more importance in the context of such disorders as retinal ischemia–reperfusion injury [ 55 ], cardiovascular diseases [ 56 ], stress-related neurodegenerative diseases [ 57 , 58 , 59 ], etc. It is worth noting that in the above cases and in many others, the key role in pathogenesis is played by dysregulation of the production of reactive oxygen species, for which the mitochondria of cells are responsible [ 60 , 61 , 62 ].…”